Craniocerebral Injury
Conditions
Keywords
L-oxiracetam, Cognitive Impairment, Craniocerebral Injury
Brief summary
A randomized, double-blind, positive drug/placebo parallel controlled, multicenter, phase III clinical trial of L-oxiracetam injection to improve memory and cognitive Impairment in patients with craniocerebral injury.
Interventions
DRUGTest group: L-oxiracetam Injection
L-oxiracetam injection, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
DRUGControl group: Oxiracetam Injection
Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Oxiracetam injection, 6 vials, once a day, IV.
DRUGPlacebo group: Placebo Injection
Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
Sponsors
Nanjing Yoko Biomedical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-75 years old (including upper and lower limits), male or female 2. Craniocerebral injury meets all of the following conditions: This diagnosis has a clear head trauma, closed head injury, or head injury with cerebrospinal fluid ear leak and / or nasal leak and / or intracranial gas accumulation; MRI or CT confirmed intracranial hemorrhage above the cerebellum (including cerebral contusion, subarachnoid hemorrhage, epidural hematoma, subdural hemorrhage, intracranial hematoma, etc.), with or without transient coma; Craniocerebral injury is classified as mild or moderate (GCS score 10-15 points); Conservative treatment. 3. Within 72 hours after head injury, patients with stable and mentally handicapped mental state examination (MMSE) scores are lower than normal. 4. The legal representative and / or patient agree to participate in this clinical trial and sign an informed consent form.
Exclusion criteria
1. People who are known or suspected to be allergic to the test drug and its ingredients. 2. After the injury, drugs that improve cognitive function such as the prohibited drugs listed in the protocol have been used. 3. With a history of severe traumatic brain injury, a history of cerebrovascular accidents, and structural craniocerebral lesions. 4. With diseases such as speech and hearing impairment that cannot cooperate with the completion of cognitive function assessment. 5. A secondary brain injury occurred after the craniocerebral injury. 6. Those who need craniotomy or extraventricular drainage. 7. Combining with other serious large organ damage or serious complications may affect the test Life. 8. Patients with active epilepsy who had seizures within 1 year. 9. Patients with severe liver and kidney disease. 10. Complicated with severe heart disease, lung disease, blood and hematopoietic diseases, gastrointestinal disease, serious or progressive disease. 11. Past or present with a malignant tumor 12. Combining neurological and mental disorders that make it impossible or unwilling to cooperate. 13. Women who are pregnant, breastfeeding or have a recent birth plan. 14. Researchers do not consider it appropriate to participate in the clinical trial. 15. Those who have participated in other clinical trials and used test drugs 3 months before the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference of Loewenstein Occupational Therapy Cognitive Assessment (LOCTA) scores between baseline and 3 months after administration of drugs. | 3 months |
Countries
China
Contacts
Primary ContactTie Xu, Master
Backup ContactHuiwen Jiao, Master
Outcome results
None listed